Hepatitis b cure hope fades as early trial ends
NCT ID NCT05345990
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This small phase 2 trial tested whether giving hepatitis B antibodies (HBIG) could clear the hepatitis B surface antigen in people with chronic hepatitis B. Only 13 patients were enrolled before the study was terminated. The goal was to see if a 12-week course of injections could make the virus undetectable, potentially reducing the need for long-term medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hepatitis B immunoglobulins (Hepatect and Zutectra)
What this could lead to
If successful, this could point toward a way to clear the hepatitis B surface antigen, potentially reducing the need for lifelong antiviral medication.
What could go wrong
This was a very small, early-phase pilot study with only 13 participants, and it was terminated early. The treatment involves frequent injections and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hannover Medical School, Department for Gastroenterology, Hepatology and Endocrinology
Hanover, Lower Saxony, 30625, Germany